Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex

Table 4

Comparing factors affecting physical and mental health in Avonex and CinnoVex groups.

Time-varying covariate		Avonex			CinnoVex		𝑃
	Baseline	Change^*	𝑃	Baseline	Change	𝑃	Baseline	Change
EDSS	1.9	0.1	0.489	1.5	0.2	0.401	0.104	0.231
MSQOL-54 measures
Physical health composite score	61.8	1.2	0.677	59.8	0.0	0.884	0.608	0.377
Mental health composite score	57.4	−2.2	0.197	53.6	1.6	0.845	0.392	0.841
Physical function	12.8	0.2	0.587	12.2	0.2	0.475	0.465	0.324
Health perception	9.9	0.2	0.559	9.9	−0.5	0.127	0.932	0.251
Energy	6.2	−0.25	0.185	5.74	0.1	0.541	0.316	0.828
Role limitation—physical	7.6	−0.2	0.914	6.3	−0.0	0.958	0.223	0.201
Bodily pain	7.6	0.1	0.640	7.5	−0.17	0.185	0.850	0.356
Sexual function	1.7	0.27	0.411	2.6	0.2	0.585	0.172	0.189
Social function	8.2	0.2	0.516	8.3	−0.0	0.877	0.904	0.756
Health distress—physical	7.4	−0.1	0.757	6.9	0.0	0.685	0.434	0.587
Health distress—mental	9.4	−0.1	0.757	9.3	0.1	0.685	0.434	0.587
Overall quality of life	6.2	2.4	0.536	5.9	0.1	0.733	0.505	0.491
Cognitive function	11.2	−0.6	0.016	10.6	−0.5	0.050	0.494	0.548
Emotional well-being	16.1	−0.2	0.713	15.3	0.6	0.205	0.516	0.995
Role limitation—emotional	13.8	−0.8	0.844	12.0	−0.1	0.896	0.442	0.544
Satisfaction with sexual function	19.1	5.6	0.221	30.2	1.5	0.698	0.169	0.368
Change in health	48.5	1.9	0.669	50.5	4.2	0.275	0.760	0.418

^* Change after a year.